S-Space College of Medicine/School of Medicine (의과대학/대학원) Cancer Research Institute (암연구소) Journal Papers (저널논문_암연구소)
Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy
- Keam, Bhumsuk; Im, Seock-Ah; Park, Sohee; Nam, Byung-Ho; Han, Sae-Won; Oh, Do-Youn; Kim, Jee Hyun; Lee, Se-Hoon; Han, Wonshik; Kim, Dong-Wan; Kim, Tae-You; Park, In Ae; Noh, Dong-Young; Heo, Dae Seog; Bang, Yung-Jue
- Issue Date
- Journal of Cancer Research and Clinical Oncology, Vol.137 No.9, pp.1301-1308
- Purpose The aim of this study was to combine clinical pathologic variables that are associated with pathologic completer response (pCR) and relapse-free survival (RFS) after neoadjuvant chemotherapy into prediction nomograms. Methods A total of 370 stage II or III breast cancer patients who received neoadjuvant docetaxel/doxorubicin chemotherapy were enrolled in this study. We developed the nomograms using logistic regression model for pCR and Cox proportional hazard regression model for RFS. Results The nomogram for pCR based on initial tumor size, estrogen receptor (ER), human epidermal growth factor receptor 2, and Ki67 had good discrimination performance (AUROC = 0.830). Multivariate Cox model identified age less than 35, initial clinical stage, pathologic stage, ER, Ki67 as prognostic factors, and the nomogram for RFS was developed based on these covariates. The concordance index for the second nomogram was 0.781, and calibration was also good. Conclusions We developed nomograms based on clinical and pathologic characteristics to predict the probability of pCR and RFS for patients receiving neoadjuvant docetaxel/doxorubicin chemotherapy.
- Files in This Item: There are no files associated with this item.